PriceTargets.com logo

Synlogic - SYBX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $65.00
  • Forecasted Upside: 3,375.94%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.87 As of 04/19/2024 01:00 AM ET
▲ +0.04 (2.19%)

This chart shows the closing price for SYBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synlogic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYBX

Analyst Price Target is $65.00
▲ +3,375.94% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $65.00, with a high forecast of $90.00 and a low forecast of $30.00. The average price target represents a 3,375.94% upside from the last price of $1.87.

This chart shows the closing price for SYBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Synlogic. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2024HC WainwrightUpgradeSell ➝ NeutralLow
2/9/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
2/9/2024HC WainwrightDowngradeBuy ➝ SellLow
2/9/2024SVB LeerinkReiterated RatingOutperform ➝ Market PerformLow
2/9/2024Chardan CapitalDowngradeBuy ➝ NeutralLow
12/11/2023Alliance Global PartnersInitiated CoverageBuy$30.00Low
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$90.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$75.00Low
6/6/2023Chardan CapitalBoost Target$82.50 ➝ $90.00Low
4/27/2023HC WainwrightReiterated RatingBuyLow
3/29/2023Chardan CapitalLower TargetBuy$105.00 ➝ $82.50Low
11/11/2022Chardan CapitalLower TargetBuy$135.00 ➝ $105.00Low
10/18/2022OppenheimerBoost TargetOutperform$90.00 ➝ $120.00Low
6/10/2022Chardan CapitalReiterated RatingBuy$135.00High
5/23/2022HC WainwrightReiterated RatingBuy$105.00Low
5/12/2022OppenheimerLower Target$105.00 ➝ $90.00High
3/18/2022OppenheimerReiterated RatingBuy$105.00Medium
3/18/2022SVB LeerinkLower TargetOutperform$165.00 ➝ $120.00High
11/24/2021OppenheimerUpgradeMarket Perform ➝ Outperform$105.00High
11/11/2021SVB LeerinkLower TargetOutperform$225.00 ➝ $165.00High
10/13/2021HC WainwrightLower TargetBuy$135.00 ➝ $105.00Medium
9/20/2021Piper SandlerBoost TargetOverweight$105.00 ➝ $135.00High
9/7/2021HC WainwrightReiterated RatingBuy$135.00Low
7/15/2021HC WainwrightSet TargetBuy$48.90Medium
7/9/2021Chardan CapitalInitiated CoverageBuy$150.00Medium
6/28/2021HC WainwrightLower TargetBuy$195.00 ➝ $135.00Low
5/18/2021SVB LeerinkReiterated RatingBuy$225.00Low
5/14/2021OppenheimerReiterated RatingHoldMedium
3/25/2021SVB LeerinkBoost TargetOutperform$150.00 ➝ $225.00Low
3/18/2021JonestradingInitiated CoverageBuy$225.00High
1/13/2021Chardan CapitalBoost TargetBuy$75.00 ➝ $150.00High
9/18/2020Chardan CapitalReiterated RatingBuy$75.00Medium
8/10/2020HC WainwrightReiterated RatingBuyHigh
5/22/2020HC WainwrightReiterated RatingBuy$195.00N/A
5/10/2020OppenheimerReiterated RatingHoldMedium
3/23/2020HC WainwrightReiterated RatingBuy$195.00Low
3/12/2020OppenheimerReiterated RatingHoldHigh
1/13/2020HC WainwrightReiterated RatingBuy$195.00High
12/11/2019HC WainwrightReiterated RatingBuy$195.00Medium
11/13/2019Piper Sandler CompaniesReiterated RatingOverweight$150.00 ➝ $105.00High
9/19/2019Chardan CapitalReiterated RatingBuyHigh
9/9/2019HC WainwrightReiterated RatingBuy$195.00High
9/4/2019Piper Sandler CompaniesSet TargetBuy$150.00Low
8/21/2019HC WainwrightLower TargetBuy$330.00 ➝ $195.00Medium
8/21/2019CitigroupDowngradeBuy ➝ Sell$300.00 ➝ $30.00High
8/20/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
8/20/2019Piper Sandler CompaniesReiterated RatingOverweight$150.00 ➝ $300.00High
8/12/2019HC WainwrightReiterated RatingBuy$330.00High
8/9/2019WedbushReiterated RatingOutperform$300.00Low
7/16/2019HC WainwrightBoost TargetBuy$300.00 ➝ $330.00High
7/15/2019Chardan CapitalSet TargetBuy$375.00High
7/15/2019Piper Sandler CompaniesBoost TargetOverweight$240.00 ➝ $300.00Low
6/24/2019HC WainwrightReiterated RatingBuy$300.00Low
6/12/2019WedbushReiterated RatingOutperform$300.00High
6/12/2019Piper Sandler CompaniesBoost TargetOverweight$225.00 ➝ $240.00High
4/30/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$270.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Synlogic logo
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.87
Low: $1.78
High: $1.89

50 Day Range

MA: $1.82
Low: $1.72
High: $1.97

52 Week Range

Now: $1.87
Low: $1.55
High: $10.20

Volume

54,373 shs

Average Volume

118,768 shs

Market Capitalization

$21.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Synlogic?

The following Wall Street sell-side analysts have issued research reports on Synlogic in the last year: Alliance Global Partners, Chardan Capital, HC Wainwright, Leerink Partnrs, and SVB Leerink LLC.
View the latest analyst ratings for SYBX.

What is the current price target for Synlogic?

3 Wall Street analysts have set twelve-month price targets for Synlogic in the last year. Their average twelve-month price target is $65.00, suggesting a possible upside of 3,375.9%. Chardan Capital has the highest price target set, predicting SYBX will reach $90.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $30.00 for Synlogic in the next year.
View the latest price targets for SYBX.

What is the current consensus analyst rating for Synlogic?

Synlogic currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SYBX, but not buy more shares or sell existing shares.
View the latest ratings for SYBX.

What other companies compete with Synlogic?

Other companies that are similar to Synlogic include Onconova Therapeutics, MEI Pharma, Yumanity Therapeutics, Lumos Pharma and Vincerx Pharma. Learn More about companies similar to Synlogic.

How do I contact Synlogic's investor relations team?

Synlogic's physical mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company's listed phone number is (617) 401-9975 and its investor relations email address is [email protected]. The official website for Synlogic is www.synlogictx.com. Learn More about contacing Synlogic investor relations.